Page 4 - Thoracic Medical Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO - (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER 1 AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal. Patients with early-stage lung cancer are treated with the intention of cure; however, many relapse because treatment is limited to surgery and adjuvant chemotherapy. 2 Unprecedented clinical trial data show that osimertinib, the first approved targeted oral therapy in this setting, can reduce the risk of disease recurrence or death by 80% in patients with early-stage (IB-IIIA) EGFR mutation-positive NSCLC versus placebo.

United kingdomUnited statesGreat britainAlex larkinsonKarun krishnaCarles escriuLe chevalierCollaborative groupNational lung cancer auditClatterbridge cancer centreArch pathol labRoyal college of physiciansData monitoring committeeRegulatory agencyNational institute for healthCancer research united kingdom